Skip to main content
Erschienen in: Nutrition Journal 1/2015

Open Access 01.12.2015 | Research

Oral consumption of α-linolenic acid increases serum BDNF levels in healthy adult humans

verfasst von: Mahmoudreza Hadjighassem, Behnam Kamalidehghan, Nima Shekarriz, Argavan Baseerat, Nima Molavi, Masoud Mehrpour, Mohammad Taghi Joghataei, Mahdi Tondar, Fatemeh Ahmadipour, Goh Yong Meng

Erschienen in: Nutrition Journal | Ausgabe 1/2015

download
DOWNLOAD
print
DRUCKEN
insite
SUCHEN

Abstract

Background aims

Dietary omega-6 and omega-3 fatty acids have remarkable impacts on the levels of DHA in the brain and retina. Low levels of DHA in plasma and blood hamper visual and neural development in children and cause dementia and cognitive decline in adults. The level of brain-derived neurotrophic factors (BDNF) changes with dietary omega-3 fatty acid intake. BDNF is known for its effects on promoting neurogenesis and neuronal survival.

Methods

In this study, we examined the effect of the oral consumption of α-Linolenic acid (ALA) on blood levels of BDNF and Malondialdehyde (MDA) in healthy adult humans. 30 healthy volunteers, 15 men and 15 women, were selected randomly. Each individual served as his or her own control. Before consuming the Flaxseed oil capsules, 5cc blood from each individual was sampled in order to measure the plasma levels of BDNF and MDA as baseline controls. During the experiment, each individual was given 3 oral capsules of flaxseed oil, containing 500mg of alpha linolenic acid, daily for one week. Then, plasma levels of BDNF and MDA were tested.

Results

The plasma levels of BDNF and MDA significantly (P < 0.05) increased in individuals who received the oral capsules of ALA. Plasma levels of BDNF increased more in the women in comparison with the men.

Conclusion

ALA treatment could be a feasible approach to reduce size of infarcts in stroke patients. Thus, ALA could be used in adjunction with routine stroke therapies to minimize brain lesions caused by stroke.
Hinweise

Competing interests

The authors declare that they have no competing interests.

Authors’ contribution

MH and MT conceived and designed the experiments. NS, AB, NM, MM, and MTJ performed the experiments and contributed to reagents/materials/analysis tools. GYM and MH analyzed the data. BK, FA, and MT wrote the manuscript; contributed to the discussion S72-91and reviewed the manuscript. All authors read and approved the final manuscript.
Abkürzungen
ALA
α-Linolenic Acid
BDNF
Braine-derived Neurotrophic Factor
DHA
Docosahexaenoic acid
MDA
Malondialdehyde

Introduction

The long chain omega-3 fatty acid with 6 double bonds and 22 carbons, docosahexaenoic acid (DHA), is the most abundant omega-3 fatty acid in the mammalian central nervous system. DHA is concentrated in the visual units of retina and membrane lipids of the brain grey matter. Levels of DHA increase during mammalian development and reduce by aging [1-5].
Many researchers have shown that dietary ω-6 and omega ω-3 fatty acids have remarkable impact on the levels of DHA in brain and retina [6,7]. Furthermore, according to many epidemiological studies, low levels of DHA in plasma and blood hamper visual and neural development in children and cause dementia and cognitive decline in adults [8-22].
A growing body of evidence indicates that omega-3 fatty acids have neuroprotective impact on the nervous system. These fatty acids influence the levels of neurotrophins, molecules that increase neuronal growth and survival. Among neurotrophins, the level of brain-derived neurotrophic factor (BDNF) changes with dietary omega-3 fatty acids intake [23,24]. BDNF is known for its effects on promoting neurogenesis and neuronal survival [25,26].
The α-Linolenic acid (ALA; 18:3n - 3) is a polyunsaturated omega-3 fatty acid that has several neuroprotective effects [27-32]. In this study, we measured the plasma levels of BDNF and MDA in two groups of healthy participants, those who received ALA and those who did not.

Material and methods

This study was evaluated and approved by the Ethical Committee of the Tehran University of Medical Sciences. Thirty healthy volunteers, fifteen men and fifteen women, were selected randomly. They read and signed a consent form prior to enrolment in this study. These individuals had Body Mass Indexes (BMI) of less than thirty, similar low-fat diets, and no underlying diseases such as diabetes or high blood pressure. Because effective doses of ALA for increasing BDNF levels are unknown, each individual served as his or her own control.
Before consuming the Flaxseed oil [(Swiss, Canada) (Table 1)], 5cc blood from each individual was sampled in order to measure the plasma levels of BDNF and MDA as baseline controls. During the experiment, each individual was given 3 oral capsules of flaxseed oil, containing 500mg of ALA, daily for one week. Then, Plasma levels of BDNF and MDA were assessed using BDNF Emax® ImmunoAssay (Promega) and colorimetric Assay (Oxford Biomedical Research) kits according to the manufacturer’s protocols, respectively.
Table 1
Flax seed oil capsules
Flax seed oil
ALA
Company
1000 mg
530 mg
Swissherbal
Each 1000 mg flax seed oil capsule contained 530 mg ALA.

Statistical analysis

GraphPad prism5 was applied to compare the levels of BDNF and MDA, after taking the capsules for one week, to their baselines. Numerical data are presented below as means ± SEM. Statistical testing used Paired t-test analysis. Each test was performed at least two times and P < 0.05 was considered significant.

Results

This study revealed that plasma BDNF levels significantly (P < 0.05) increased in individuals who received the oral capsules of ALA (Figure 1). In order to determine whether or not this phenomenon was associated with peroxidation of fatty acids, plasma levels of MDA in the ALA group were measured, and they notably (p < 0.05) increased. (Figure 2).
In addition, plasma levels of BDNF increased more in the women in comparison with the men. Although we observed a significant positive trend in increasing the BDNF levels in the men (P = 0.01) (Table 2, Figure 3).
Table 2
Data analysis of serum BDNF levels in males and females
Sex
 
Pretreatment
Post-treatment
P value
 
Mean
Female
0.7987
1.036
0.005
Std.Deviation
 
0.1740
0.2035
 
Mean
Male
0.8872
1.096
0.01
Std.Deviation
 
0.1270
0.1986
 

Discussion

The neuroprotective roles of ALA have been reported in several stroke studies [27,31-36]. Recently, several molecular and clinical studies emphasized on the therapeutic potential of Omega-3 polyunsaturated fatty acids for treating a number of neurological and psychiatric diseases. Nevertheless, the mechanisms underlying these effects are still poorly understood.
In 2009, Blondeau et al. showed that subchronic ALA injections in mice induced neurogenesis in the hippocampus, increased in vivo and in vitro BDNF expression, promoted Neural Stem cell (NSCs) proliferation and synaptogenesis, enhanced synaptic vesicle fusion and protein levels, and induced antidepressant-like behavior. Furthermore, they observed that pre- and post-treatments with repeated ALA injections decreased the infarc volumes and mortality caused by middle cerebral artery occlusion (MCAO) [37]. Nguemeni et al. in 2010 reported that dietary supplements of ALA in an enriched rapeseed oil diet could significantly reduce the MCAO-induced mortality rate and infarct volumes in mice [38]. In light of these studies on ALA, we examined the effect of dietary consumption of ALA on the blood levels of BDNF and MDA. To the best of our knowledge, this is the first study on healthy adult humans that measured both BDNF and MDA levels, used oral consumption of ALA, and determined sex differences in response to ALA intake. The results demonstrated that the levels of BDNF and MDA both increased in individuals who took ALA.
Neurotrophins are small proteins that are crucial for neuronal differentiation, growth, survival, and plasticity [39]. Nerve growth factor (NGF), brain-derived neurotrophic factor (BDNF), neurotrophin-3 (NT-3), and neurotrophin-4/5 (NT-4/5) are members of the mammalian neurotrophin family. The impact of these molecules on the nervous system is mediated by the tropomyosin receptor kinase (Trk) receptors and membrane-bound receptor tyrosine kinases that activate a number of cell signaling pathways which are linked to growth, differentiation, and survival [40]. The importance of neurotrophin signaling in brain development is well elucidated with findings that showed that knockout mice for any of the neurotrophins or their receptors were fatal or exhibited severe neural defects [41]. Neurotrophin signallings have important roles in the survival and integration of new neurons. For instance, BDNF triggers the TrkB receptor tyrosine kinases. BDNF also increases the number and survival of NSCs in the subventricular zone (SVZ) and olfactory bulbs [42,43]. Likewise, knocking down the TrkB receptors or disrupting the BDNF signaling pathway in dentate gyrus progenitors can lead to the formation of shorter dendrites, reduced spine, and eventually death [44].
BDNF signaling promotes the survival of newly-generated neurons. In addition, defects in this pathway are associated with decreased neuronal survival and neurogenesis as well as the incidence and progression of several neurological disorders, such as schizophrenia, bipolar disorder, Alzheimer’s disease, and age-related cognitive decline [43,45,46]. Furthermore, BDNF indirectly increases the transcription of Bcl-w gene, an anti-apoptotic member of the Bcl-2 family [47]. Thus, BDNF decreases neuronal apoptosis. In addition, BDNF increases adhesion, migration, and survival of neurons. This neurotrophic molecule also enhances neurogenesis, synaptic plasticity, and neuronal differentiation through the BDNF/TrkB-TK+ signaling pathway, an important pathway for neuronal viability and function [48-57].
ALA treatment can be beneficial for the treatment of many neurological diseases, particularly stroke, which is the third leading cause of death worldwide [58,59]. Our findings were in accordance with the previous studies, confirming that ALA increases the expression of BDNF. Considering the neuroprotective and neurotrophic characteristics of BDNF, ALA treatment could be a feasible approach to reduce infarct size in stroke patients. Thus, ALA could be used in adjunction with routine stroke treatments to minimize lesions caused by stroke. Further research could attempt to replicate the present findings with a larger sample size. Furthermore, studying the molecular mechanisms underlying the positive effects of ALA on the nervous system might also be helpful. Future research can investigate the effects of ALA intake on stroke patients.

Acknowledgements

This research was funded by a grant from the Cellular and Molecular Research Center at the Iran University of Medical Sciences (No. 12507).
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://​creativecommons.​org/​licenses/​by/​4.​0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://​creativecommons.​org/​publicdomain/​zero/​1.​0/​) applies to the data made available in this article, unless otherwise stated.

Competing interests

The authors declare that they have no competing interests.

Authors’ contribution

MH and MT conceived and designed the experiments. NS, AB, NM, MM, and MTJ performed the experiments and contributed to reagents/materials/analysis tools. GYM and MH analyzed the data. BK, FA, and MT wrote the manuscript; contributed to the discussion S72-91and reviewed the manuscript. All authors read and approved the final manuscript.
Literatur
1.
Zurück zum Zitat Giusto NM, Salvador GA, Castagnet PI, Pasquare SJ, Ilincheta de Boschero MG. Age-associated changes in central nervous system glycerolipid composition and metabolism. Neurochem Res. 2002;27:1513–23.CrossRefPubMed Giusto NM, Salvador GA, Castagnet PI, Pasquare SJ, Ilincheta de Boschero MG. Age-associated changes in central nervous system glycerolipid composition and metabolism. Neurochem Res. 2002;27:1513–23.CrossRefPubMed
2.
Zurück zum Zitat Martinez M. Tissue levels of polyunsaturated fatty acids during early human development. J Pediatr. 1992;120:S129–38.CrossRefPubMed Martinez M. Tissue levels of polyunsaturated fatty acids during early human development. J Pediatr. 1992;120:S129–38.CrossRefPubMed
3.
Zurück zum Zitat Rotstein NP, Ilincheta de Boschero MG, Giusto NM, Aveldano MI. Effects of aging on the composition and metabolism of docosahexaenoate-containing lipids of retina. Lipids. 1987;22:253–60.CrossRefPubMed Rotstein NP, Ilincheta de Boschero MG, Giusto NM, Aveldano MI. Effects of aging on the composition and metabolism of docosahexaenoate-containing lipids of retina. Lipids. 1987;22:253–60.CrossRefPubMed
4.
Zurück zum Zitat Soderberg M, Edlund C, Kristensson K, Dallner G. Lipid compositions of different regions of the human brain during aging. J Neurochem. 1990;54:415–23.CrossRefPubMed Soderberg M, Edlund C, Kristensson K, Dallner G. Lipid compositions of different regions of the human brain during aging. J Neurochem. 1990;54:415–23.CrossRefPubMed
5.
Zurück zum Zitat Svennerholm L. Distribution and fatty acid composition of phosphoglycerides in normal human brain. J Lipid Res. 1968;9:570–9.PubMed Svennerholm L. Distribution and fatty acid composition of phosphoglycerides in normal human brain. J Lipid Res. 1968;9:570–9.PubMed
6.
7.
Zurück zum Zitat Innis SM. Essential fatty acid metabolism during early development. In: Biology of Metabolism in Growing Animals. B.V. Amsterdam: Elsevier Science; 2005. Innis SM. Essential fatty acid metabolism during early development. In: Biology of Metabolism in Growing Animals. B.V. Amsterdam: Elsevier Science; 2005.
8.
Zurück zum Zitat Bouwstra H, Dijck-Brouwer DA, Wildeman JA, Tjoonk HM, van der Heide JC, Boersma ER, et al. Long-chain polyunsaturated fatty acids have a positive effect on the quality of general movements of healthy term infants. Am J Clin Nutr. 2003;78:313–8.PubMed Bouwstra H, Dijck-Brouwer DA, Wildeman JA, Tjoonk HM, van der Heide JC, Boersma ER, et al. Long-chain polyunsaturated fatty acids have a positive effect on the quality of general movements of healthy term infants. Am J Clin Nutr. 2003;78:313–8.PubMed
9.
Zurück zum Zitat Dullemeijer C, Durga J, Brouwer IA, van de Rest O, Kok FJ, Brummer RJ, et al. n 3 fatty acid proportions in plasma and cognitive performance in older adults. Am J Clin Nutr. 2007;86:1479–85.PubMed Dullemeijer C, Durga J, Brouwer IA, van de Rest O, Kok FJ, Brummer RJ, et al. n 3 fatty acid proportions in plasma and cognitive performance in older adults. Am J Clin Nutr. 2007;86:1479–85.PubMed
10.
Zurück zum Zitat Dunstan JA, Simmer K, Dixon G, Prescott SL. Cognitive assessment of children at age 2(1/2) years after maternal fish oil supplementation in pregnancy: a randomised controlled trial. Arch Dis Child Fetal Neonatal Ed. 2008;93:F45–50.CrossRefPubMed Dunstan JA, Simmer K, Dixon G, Prescott SL. Cognitive assessment of children at age 2(1/2) years after maternal fish oil supplementation in pregnancy: a randomised controlled trial. Arch Dis Child Fetal Neonatal Ed. 2008;93:F45–50.CrossRefPubMed
11.
Zurück zum Zitat Helland IB, Smith L, Saarem K, Saugstad OD, Drevon CA. Maternal supplementation with very-long-chain n-3 fatty acids during pregnancy and lactation augments children’s IQ at 4 years of age. Pediatrics. 2003;111:e39–44.CrossRefPubMed Helland IB, Smith L, Saarem K, Saugstad OD, Drevon CA. Maternal supplementation with very-long-chain n-3 fatty acids during pregnancy and lactation augments children’s IQ at 4 years of age. Pediatrics. 2003;111:e39–44.CrossRefPubMed
12.
Zurück zum Zitat Hibbeln JR, Davis JM, Steer C, Emmett P, Rogers I, Williams C, et al. Maternal seafood consumption in pregnancy and neurodevelopmental outcomes in childhood (ALSPAC study): an observational cohort study. Lancet. 2007;369:578–85.CrossRefPubMed Hibbeln JR, Davis JM, Steer C, Emmett P, Rogers I, Williams C, et al. Maternal seafood consumption in pregnancy and neurodevelopmental outcomes in childhood (ALSPAC study): an observational cohort study. Lancet. 2007;369:578–85.CrossRefPubMed
13.
Zurück zum Zitat Innis SM, Friesen RW. Essential n-3 fatty acids in pregnant women and early visual acuity maturation in term infants. Am J Clin Nutr. 2008;87:548–57.PubMed Innis SM, Friesen RW. Essential n-3 fatty acids in pregnant women and early visual acuity maturation in term infants. Am J Clin Nutr. 2008;87:548–57.PubMed
14.
Zurück zum Zitat Innis SM, Gilley J, Werker J. Are human milk long-chain polyunsaturated fatty acids related to visual and neural development in breast-fed term infants? J Pediatr. 2001;139:532–8.CrossRefPubMed Innis SM, Gilley J, Werker J. Are human milk long-chain polyunsaturated fatty acids related to visual and neural development in breast-fed term infants? J Pediatr. 2001;139:532–8.CrossRefPubMed
15.
Zurück zum Zitat Kalmijn S, van Boxtel MP, Ocke M, Verschuren WM, Kromhout D, Launer LJ. Dietary intake of fatty acids and fish in relation to cognitive performance at middle age. Neurology. 2004;62:275–80.CrossRefPubMed Kalmijn S, van Boxtel MP, Ocke M, Verschuren WM, Kromhout D, Launer LJ. Dietary intake of fatty acids and fish in relation to cognitive performance at middle age. Neurology. 2004;62:275–80.CrossRefPubMed
16.
Zurück zum Zitat Morris MC, Evans DA, Bienias JL, Tangney CC, Bennett DA, Wilson RS, et al. Consumption of fish and n-3 fatty acids and risk of incident Alzheimer disease. Arch Neurol. 2003;60:940–6.CrossRefPubMed Morris MC, Evans DA, Bienias JL, Tangney CC, Bennett DA, Wilson RS, et al. Consumption of fish and n-3 fatty acids and risk of incident Alzheimer disease. Arch Neurol. 2003;60:940–6.CrossRefPubMed
17.
Zurück zum Zitat Nurk E, Drevon CA, Refsum H, Solvoll K, Vollset SE, Nygard O, et al. Cognitive performance among the elderly and dietary fish intake: the Hordaland Health Study. Am J Clin Nutr. 2007;86:1470–8.PubMed Nurk E, Drevon CA, Refsum H, Solvoll K, Vollset SE, Nygard O, et al. Cognitive performance among the elderly and dietary fish intake: the Hordaland Health Study. Am J Clin Nutr. 2007;86:1470–8.PubMed
18.
Zurück zum Zitat Oken E, Wright RO, Kleinman KP, Bellinger D, Amarasiriwardena CJ, Hu H, et al. Maternal fish consumption, hair mercury, and infant cognition in a U.S. Cohort. Environ Health Perspect. 2005;113:1376–80.CrossRefPubMedPubMedCentral Oken E, Wright RO, Kleinman KP, Bellinger D, Amarasiriwardena CJ, Hu H, et al. Maternal fish consumption, hair mercury, and infant cognition in a U.S. Cohort. Environ Health Perspect. 2005;113:1376–80.CrossRefPubMedPubMedCentral
19.
Zurück zum Zitat Schaeffer L, Gohlke H, Muller M, Heid IM, Palmer LJ, Kompauer I, et al. Common genetic variants of the FADS1 FADS2 gene cluster and their reconstructed haplotypes are associated with the fatty acid composition in phospholipids. Hum Mol Genet. 2006;15:1745–56.CrossRefPubMed Schaeffer L, Gohlke H, Muller M, Heid IM, Palmer LJ, Kompauer I, et al. Common genetic variants of the FADS1 FADS2 gene cluster and their reconstructed haplotypes are associated with the fatty acid composition in phospholipids. Hum Mol Genet. 2006;15:1745–56.CrossRefPubMed
20.
Zurück zum Zitat Uauy R, Dangour AD. Nutrition in brain development and aging: role of essential fatty acids. Nutr Rev. 2006;64:S24–33. discussion S72-91.CrossRefPubMed Uauy R, Dangour AD. Nutrition in brain development and aging: role of essential fatty acids. Nutr Rev. 2006;64:S24–33. discussion S72-91.CrossRefPubMed
21.
Zurück zum Zitat van Gelder BM, Tijhuis M, Kalmijn S, Kromhout D. Fish consumption, n-3 fatty acids, and subsequent 5-y cognitive decline in elderly men: the Zutphen Elderly Study. Am J Clin Nutr. 2007;85:1142–7.PubMed van Gelder BM, Tijhuis M, Kalmijn S, Kromhout D. Fish consumption, n-3 fatty acids, and subsequent 5-y cognitive decline in elderly men: the Zutphen Elderly Study. Am J Clin Nutr. 2007;85:1142–7.PubMed
22.
Zurück zum Zitat Williams C, Birch EE, Emmett PM, Northstone K. Avon Longitudinal Study of P, Childhood Study T. Stereoacuity at age 3.5 y in children born full-term is associated with prenatal and postnatal dietary factors: a report from a population-based cohort study. Am J Clin Nutr. 2001;73:316–22.PubMed Williams C, Birch EE, Emmett PM, Northstone K. Avon Longitudinal Study of P, Childhood Study T. Stereoacuity at age 3.5 y in children born full-term is associated with prenatal and postnatal dietary factors: a report from a population-based cohort study. Am J Clin Nutr. 2001;73:316–22.PubMed
24.
Zurück zum Zitat Wu A, Ying Z, Gomez-Pinilla F. Dietary omega-3 fatty acids normalize BDNF levels, reduce oxidative damage, and counteract learning disability after traumatic brain injury in rats. J Neurotrauma. 2004;21:1457–67.CrossRefPubMed Wu A, Ying Z, Gomez-Pinilla F. Dietary omega-3 fatty acids normalize BDNF levels, reduce oxidative damage, and counteract learning disability after traumatic brain injury in rats. J Neurotrauma. 2004;21:1457–67.CrossRefPubMed
25.
Zurück zum Zitat Loeliger MM, Briscoe T, Rees SM. BDNF increases survival of retinal dopaminergic neurons after prenatal compromise. Invest Ophthalmol Vis Sci. 2008;49:1282–9.CrossRefPubMed Loeliger MM, Briscoe T, Rees SM. BDNF increases survival of retinal dopaminergic neurons after prenatal compromise. Invest Ophthalmol Vis Sci. 2008;49:1282–9.CrossRefPubMed
26.
Zurück zum Zitat Mattson MP, Maudsley S, Martin B. A neural signaling triumvirate that influences ageing and age-related disease: insulin/IGF-1, BDNF and serotonin. Ageing Res Rev. 2004;3:445–64.CrossRefPubMed Mattson MP, Maudsley S, Martin B. A neural signaling triumvirate that influences ageing and age-related disease: insulin/IGF-1, BDNF and serotonin. Ageing Res Rev. 2004;3:445–64.CrossRefPubMed
27.
Zurück zum Zitat Blondeau N, Widmann C, Lazdunski M, Heurteaux C. Polyunsaturated fatty acids induce ischemic and epileptic tolerance. Neuroscience. 2002;109:231–41.CrossRefPubMed Blondeau N, Widmann C, Lazdunski M, Heurteaux C. Polyunsaturated fatty acids induce ischemic and epileptic tolerance. Neuroscience. 2002;109:231–41.CrossRefPubMed
28.
Zurück zum Zitat Heurteaux C, Guy N, Laigle C, Blondeau N, Duprat F, Mazzuca M, et al. TREK-1, a K+ channel involved in neuroprotection and general anesthesia. EMBO J. 2004;23:2684–95.CrossRefPubMedPubMedCentral Heurteaux C, Guy N, Laigle C, Blondeau N, Duprat F, Mazzuca M, et al. TREK-1, a K+ channel involved in neuroprotection and general anesthesia. EMBO J. 2004;23:2684–95.CrossRefPubMedPubMedCentral
29.
Zurück zum Zitat Huang WL, King VR, Curran OE, Dyall SC, Ward RE, Lal N, et al. A combination of intravenous and dietary docosahexaenoic acid significantly improves outcome after spinal cord injury. Brain. 2007;130:3004–19.CrossRefPubMed Huang WL, King VR, Curran OE, Dyall SC, Ward RE, Lal N, et al. A combination of intravenous and dietary docosahexaenoic acid significantly improves outcome after spinal cord injury. Brain. 2007;130:3004–19.CrossRefPubMed
30.
Zurück zum Zitat King VR, Huang WL, Dyall SC, Curran OE, Priestley JV, Michael-Titus AT. Omega-3 fatty acids improve recovery, whereas omega-6 fatty acids worsen outcome, after spinal cord injury in the adult rat. J Neurosci. 2006;26:4672–80.CrossRefPubMed King VR, Huang WL, Dyall SC, Curran OE, Priestley JV, Michael-Titus AT. Omega-3 fatty acids improve recovery, whereas omega-6 fatty acids worsen outcome, after spinal cord injury in the adult rat. J Neurosci. 2006;26:4672–80.CrossRefPubMed
31.
Zurück zum Zitat Lang-Lazdunski L, Blondeau N, Jarretou G, Lazdunski M, Heurteaux C. Linolenic acid prevents neuronal cell death and paraplegia after transient spinal cord ischemia in rats. J Vasc Surg. 2003;38:564–75.CrossRefPubMed Lang-Lazdunski L, Blondeau N, Jarretou G, Lazdunski M, Heurteaux C. Linolenic acid prevents neuronal cell death and paraplegia after transient spinal cord ischemia in rats. J Vasc Surg. 2003;38:564–75.CrossRefPubMed
32.
Zurück zum Zitat Lauritzen I, Blondeau N, Heurteaux C, Widmann C, Romey G, Lazdunski M. Polyunsaturated fatty acids are potent neuroprotectors. EMBO J. 2000;19:1784–93.CrossRefPubMedPubMedCentral Lauritzen I, Blondeau N, Heurteaux C, Widmann C, Romey G, Lazdunski M. Polyunsaturated fatty acids are potent neuroprotectors. EMBO J. 2000;19:1784–93.CrossRefPubMedPubMedCentral
33.
Zurück zum Zitat Blondeau N, Petrault O, Manta S, Giordanengo V, Gounon P, Bordet R, et al. Polyunsaturated fatty acids are cerebral vasodilators via the TREK-1 potassium channel. Circ Res. 2007;101:176–84.CrossRefPubMed Blondeau N, Petrault O, Manta S, Giordanengo V, Gounon P, Bordet R, et al. Polyunsaturated fatty acids are cerebral vasodilators via the TREK-1 potassium channel. Circ Res. 2007;101:176–84.CrossRefPubMed
34.
Zurück zum Zitat Blondeau N, Widmann C, Lazdunski M, Heurteaux C. Activation of the nuclear factor-kappaB is a key event in brain tolerance. J Neurosci. 2001;21:4668–77.PubMed Blondeau N, Widmann C, Lazdunski M, Heurteaux C. Activation of the nuclear factor-kappaB is a key event in brain tolerance. J Neurosci. 2001;21:4668–77.PubMed
35.
Zurück zum Zitat Heurteaux C, Laigle C, Blondeau N, Jarretou G, Lazdunski M. Alpha-linolenic acid and riluzole treatment confer cerebral protection and improve survival after focal brain ischemia. Neuroscience. 2006;137:241–51.CrossRefPubMed Heurteaux C, Laigle C, Blondeau N, Jarretou G, Lazdunski M. Alpha-linolenic acid and riluzole treatment confer cerebral protection and improve survival after focal brain ischemia. Neuroscience. 2006;137:241–51.CrossRefPubMed
36.
Zurück zum Zitat Xiao YF, Wright SN, Wang GK, Morgan JP, Leaf A. Fatty acids suppress voltage-gated Na + currents in HEK293t cells transfected with the alpha-subunit of the human cardiac Na + channel. Proc Natl Acad Sci U S A. 1998;95:2680–5.CrossRefPubMedPubMedCentral Xiao YF, Wright SN, Wang GK, Morgan JP, Leaf A. Fatty acids suppress voltage-gated Na + currents in HEK293t cells transfected with the alpha-subunit of the human cardiac Na + channel. Proc Natl Acad Sci U S A. 1998;95:2680–5.CrossRefPubMedPubMedCentral
37.
Zurück zum Zitat Blondeau N, Nguemeni C, Debruyne DN, Piens M, Wu X, Pan H, et al. Subchronic alpha-linolenic acid treatment enhances brain plasticity and exerts an antidepressant effect: a versatile potential therapy for stroke. Neuropsychopharmacology. 2009;34:2548–59.CrossRefPubMed Blondeau N, Nguemeni C, Debruyne DN, Piens M, Wu X, Pan H, et al. Subchronic alpha-linolenic acid treatment enhances brain plasticity and exerts an antidepressant effect: a versatile potential therapy for stroke. Neuropsychopharmacology. 2009;34:2548–59.CrossRefPubMed
38.
Zurück zum Zitat Nguemeni C, Delplanque B, Rovere C, Simon-Rousseau N, Gandin C, Agnani G, et al. Dietary supplementation of alpha-linolenic acid in an enriched rapeseed oil diet protects from stroke. Pharmacol Res. 2010;61:226–33.CrossRefPubMed Nguemeni C, Delplanque B, Rovere C, Simon-Rousseau N, Gandin C, Agnani G, et al. Dietary supplementation of alpha-linolenic acid in an enriched rapeseed oil diet protects from stroke. Pharmacol Res. 2010;61:226–33.CrossRefPubMed
39.
Zurück zum Zitat Schindowski K, Belarbi K, Buee L. Neurotrophic factors in Alzheimer’s disease: role of axonal transport. Genes Brain Behav. 2008;7 Suppl 1:43–56.CrossRefPubMedPubMedCentral Schindowski K, Belarbi K, Buee L. Neurotrophic factors in Alzheimer’s disease: role of axonal transport. Genes Brain Behav. 2008;7 Suppl 1:43–56.CrossRefPubMedPubMedCentral
40.
Zurück zum Zitat Patapoutian A, Reichardt LF. Trk receptors: mediators of neurotrophin action. Curr Opin Neurobiol. 2001;11:272–80.CrossRefPubMed Patapoutian A, Reichardt LF. Trk receptors: mediators of neurotrophin action. Curr Opin Neurobiol. 2001;11:272–80.CrossRefPubMed
41.
Zurück zum Zitat Bartkowska K, Turlejski K, Djavadian RL. Neurotrophins and their receptors in early development of the mammalian nervous system. Acta Neurobiol Exp. 2010;70:454–67. Bartkowska K, Turlejski K, Djavadian RL. Neurotrophins and their receptors in early development of the mammalian nervous system. Acta Neurobiol Exp. 2010;70:454–67.
42.
Zurück zum Zitat Bath KG, Mandairon N, Jing D, Rajagopal R, Kapoor R, Chen ZY, et al. Variant brain-derived neurotrophic factor (Val66Met) alters adult olfactory bulb neurogenesis and spontaneous olfactory discrimination. J Neurosci. 2008;28:2383–93.CrossRefPubMedPubMedCentral Bath KG, Mandairon N, Jing D, Rajagopal R, Kapoor R, Chen ZY, et al. Variant brain-derived neurotrophic factor (Val66Met) alters adult olfactory bulb neurogenesis and spontaneous olfactory discrimination. J Neurosci. 2008;28:2383–93.CrossRefPubMedPubMedCentral
43.
Zurück zum Zitat Kirschenbaum B, Goldman SA. Brain-derived neurotrophic factor promotes the survival of neurons arising from the adult rat forebrain subependymal zone. Proc Natl Acad Sci U S A. 1995;92:210–4.CrossRefPubMedPubMedCentral Kirschenbaum B, Goldman SA. Brain-derived neurotrophic factor promotes the survival of neurons arising from the adult rat forebrain subependymal zone. Proc Natl Acad Sci U S A. 1995;92:210–4.CrossRefPubMedPubMedCentral
44.
Zurück zum Zitat Bergami M, Rimondini R, Santi S, Blum R, Gotz M, Canossa M. Deletion of TrkB in adult progenitors alters newborn neuron integration into hippocampal circuits and increases anxiety-like behavior. Proc Natl Acad Sci U S A. 2008;105:15570–5.CrossRefPubMedPubMedCentral Bergami M, Rimondini R, Santi S, Blum R, Gotz M, Canossa M. Deletion of TrkB in adult progenitors alters newborn neuron integration into hippocampal circuits and increases anxiety-like behavior. Proc Natl Acad Sci U S A. 2008;105:15570–5.CrossRefPubMedPubMedCentral
46.
Zurück zum Zitat Nagahara AH, Tuszynski MH. Potential therapeutic uses of BDNF in neurological and psychiatric disorders. Nat Rev Drug Discov. 2011;10:209–19.CrossRefPubMed Nagahara AH, Tuszynski MH. Potential therapeutic uses of BDNF in neurological and psychiatric disorders. Nat Rev Drug Discov. 2011;10:209–19.CrossRefPubMed
47.
Zurück zum Zitat Pazyra-Murphy MF, Hans A, Courchesne SL, Karch C, Cosker KE, Heerssen HM, et al. A retrograde neuronal survival response: target-derived neurotrophins regulate MEF2D and bcl-w. J Neurosci. 2009;29:6700–9.CrossRefPubMedPubMedCentral Pazyra-Murphy MF, Hans A, Courchesne SL, Karch C, Cosker KE, Heerssen HM, et al. A retrograde neuronal survival response: target-derived neurotrophins regulate MEF2D and bcl-w. J Neurosci. 2009;29:6700–9.CrossRefPubMedPubMedCentral
48.
Zurück zum Zitat Allen SJ, Wilcock GK, Dawbarn D. Profound and selective loss of catalytic TrkB immunoreactivity in Alzheimer’s disease. Biochem Biophys Res Commun. 1999;264:648–51.CrossRefPubMed Allen SJ, Wilcock GK, Dawbarn D. Profound and selective loss of catalytic TrkB immunoreactivity in Alzheimer’s disease. Biochem Biophys Res Commun. 1999;264:648–51.CrossRefPubMed
49.
Zurück zum Zitat Connor B, Young D, Yan Q, Faull RL, Synek B, Dragunow M. Brain-derived neurotrophic factor is reduced in Alzheimer’s disease. Brain Res Mol Brain Res. 1997;49:71–81.CrossRefPubMed Connor B, Young D, Yan Q, Faull RL, Synek B, Dragunow M. Brain-derived neurotrophic factor is reduced in Alzheimer’s disease. Brain Res Mol Brain Res. 1997;49:71–81.CrossRefPubMed
50.
Zurück zum Zitat Fahnestock M, Garzon D, Holsinger RM, Michalski B. Neurotrophic factors and Alzheimer’s disease: are we focusing on the wrong molecule? J Neural Transm Suppl. 2002;62:241–52.CrossRefPubMed Fahnestock M, Garzon D, Holsinger RM, Michalski B. Neurotrophic factors and Alzheimer’s disease: are we focusing on the wrong molecule? J Neural Transm Suppl. 2002;62:241–52.CrossRefPubMed
51.
Zurück zum Zitat Ferrer I, Marin C, Rey MJ, Ribalta T, Goutan E, Blanco R, et al. BDNF and full-length and truncated TrkB expression in Alzheimer disease. Implications in therapeutic strategies. J Neuropathol Exp Neurol. 1999;58:729–39.CrossRefPubMed Ferrer I, Marin C, Rey MJ, Ribalta T, Goutan E, Blanco R, et al. BDNF and full-length and truncated TrkB expression in Alzheimer disease. Implications in therapeutic strategies. J Neuropathol Exp Neurol. 1999;58:729–39.CrossRefPubMed
52.
Zurück zum Zitat Garzon D, Yu G, Fahnestock M. A new brain-derived neurotrophic factor transcript and decrease in brain-derived neurotrophic factor transcripts 1, 2 and 3 in Alzheimer’s disease parietal cortex. J Neurochem. 2002;82:1058–64.CrossRefPubMed Garzon D, Yu G, Fahnestock M. A new brain-derived neurotrophic factor transcript and decrease in brain-derived neurotrophic factor transcripts 1, 2 and 3 in Alzheimer’s disease parietal cortex. J Neurochem. 2002;82:1058–64.CrossRefPubMed
53.
Zurück zum Zitat Hock C, Heese K, Hulette C, Rosenberg C, Otten U. Region-specific neurotrophin imbalances in Alzheimer disease: decreased levels of brain-derived neurotrophic factor and increased levels of nerve growth factor in hippocampus and cortical areas. Arch Neurol. 2000;57:846–51.CrossRefPubMed Hock C, Heese K, Hulette C, Rosenberg C, Otten U. Region-specific neurotrophin imbalances in Alzheimer disease: decreased levels of brain-derived neurotrophic factor and increased levels of nerve growth factor in hippocampus and cortical areas. Arch Neurol. 2000;57:846–51.CrossRefPubMed
54.
Zurück zum Zitat Holsinger RM, Schnarr J, Henry P, Castelo VT, Fahnestock M. Quantitation of BDNF mRNA in human parietal cortex by competitive reverse transcription-polymerase chain reaction: decreased levels in Alzheimer’s disease. Brain Res Mol Brain Res. 2000;76:347–54.CrossRefPubMed Holsinger RM, Schnarr J, Henry P, Castelo VT, Fahnestock M. Quantitation of BDNF mRNA in human parietal cortex by competitive reverse transcription-polymerase chain reaction: decreased levels in Alzheimer’s disease. Brain Res Mol Brain Res. 2000;76:347–54.CrossRefPubMed
55.
Zurück zum Zitat Michalski B, Fahnestock M. Pro-brain-derived neurotrophic factor is decreased in parietal cortex in Alzheimer’s disease. Brain Res Mol Brain Res. 2003;111:148–54.CrossRefPubMed Michalski B, Fahnestock M. Pro-brain-derived neurotrophic factor is decreased in parietal cortex in Alzheimer’s disease. Brain Res Mol Brain Res. 2003;111:148–54.CrossRefPubMed
56.
Zurück zum Zitat Peng S, Wuu J, Mufson EJ, Fahnestock M. Precursor form of brain-derived neurotrophic factor and mature brain-derived neurotrophic factor are decreased in the pre-clinical stages of Alzheimer’s disease. J Neurochem. 2005;93:1412–21.CrossRefPubMed Peng S, Wuu J, Mufson EJ, Fahnestock M. Precursor form of brain-derived neurotrophic factor and mature brain-derived neurotrophic factor are decreased in the pre-clinical stages of Alzheimer’s disease. J Neurochem. 2005;93:1412–21.CrossRefPubMed
57.
Zurück zum Zitat Phillips HS, Hains JM, Armanini M, Laramee GR, Johnson SA, Winslow JW. BDNF mRNA is decreased in the hippocampus of individuals with Alzheimer’s disease. Neuron. 1991;7:695–702.CrossRefPubMed Phillips HS, Hains JM, Armanini M, Laramee GR, Johnson SA, Winslow JW. BDNF mRNA is decreased in the hippocampus of individuals with Alzheimer’s disease. Neuron. 1991;7:695–702.CrossRefPubMed
58.
Zurück zum Zitat Lloyd-Jones D, Adams RJ, Brown TM, Carnethon M, Dai S, De Simone G, et al. Executive summary: heart disease and stroke statistics–2010 update: a report from the American Heart Association. Circulation. 2010;121:948–54.CrossRefPubMed Lloyd-Jones D, Adams RJ, Brown TM, Carnethon M, Dai S, De Simone G, et al. Executive summary: heart disease and stroke statistics–2010 update: a report from the American Heart Association. Circulation. 2010;121:948–54.CrossRefPubMed
59.
Zurück zum Zitat Rosamond W, Flegal K, Furie K, Go A, Greenlund K, Haase N, et al. Heart disease and stroke statistics–2008 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation. 2008;117:e25–146.CrossRefPubMed Rosamond W, Flegal K, Furie K, Go A, Greenlund K, Haase N, et al. Heart disease and stroke statistics–2008 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation. 2008;117:e25–146.CrossRefPubMed
Metadaten
Titel
Oral consumption of α-linolenic acid increases serum BDNF levels in healthy adult humans
verfasst von
Mahmoudreza Hadjighassem
Behnam Kamalidehghan
Nima Shekarriz
Argavan Baseerat
Nima Molavi
Masoud Mehrpour
Mohammad Taghi Joghataei
Mahdi Tondar
Fatemeh Ahmadipour
Goh Yong Meng
Publikationsdatum
01.12.2015
Verlag
BioMed Central
Erschienen in
Nutrition Journal / Ausgabe 1/2015
Elektronische ISSN: 1475-2891
DOI
https://doi.org/10.1186/s12937-015-0012-5

Weitere Artikel der Ausgabe 1/2015

Nutrition Journal 1/2015 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Reizdarmsyndrom: Diäten wirksamer als Medikamente

29.04.2024 Reizdarmsyndrom Nachrichten

Bei Reizdarmsyndrom scheinen Diäten, wie etwa die FODMAP-arme oder die kohlenhydratreduzierte Ernährung, effektiver als eine medikamentöse Therapie zu sein. Das hat eine Studie aus Schweden ergeben, die die drei Therapieoptionen im direkten Vergleich analysierte.

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.